| |APRIL 20269MGM HEALTHCARE BUILDS WORLD'S LARGEST INTESTINAL REHAB HUBASTRAZENECA COPD DRUG TOZORAKIMAB CUTS FLARE UPS IN LATE STAGE TRIALSChennai-based MGM Healthcare has set up what it says is the world's largest intestinal rehabilitation programme and intestinal transplant programme in just three years, marking a significant step forward for advanced healthcare in India.The hospital has carried out more than 40 intestinal transplants since starting the programme, including 21 procedures in 2025 alone, the highest number performed globally in a single year. The initiative is led by Dr Anil Vaidya, who explained that the goal was not just to perform surgeries but to build a complete care system. This includes pre-surgery preparation, transplant procedures, rehabilitation, infection control, and long-term follow-up.Intestinal transplantation is one of the most complex proce-dures in modern medicine. It involves replacing a damaged in-testine with a donor organ, helping patients regain nutrient ab-sorption and normal digestion. According to the hospital, patient survival rates are now comparable to global medical standards in leading centres across the United States and Europe.One of the most notable achievements of the programme is that nearly 98% of patients no longer depend on total parenteral nutrition (TPN), a method where nutrients are delivered directly into the bloodstream. Long-term use of TPN can lead to serious complications such as infections and liver damage, so reducing this dependence is a major improvement in patient recovery and quality of life.The programme has also introduced India's first transplant oncology initiative. This allows intestinal transplantation to be used as a treatment option for patients with pseudomyxoma peritonei, a rare and often difficult-to-treat cancer.Hospital officials say the success is driven by innovations such as a home-based nutrition programme, improved infection control methods, and a specialised system to safely transport patients from across the country--strengthening India's medical innovation landscape.With these developments, Chennai is increasingly being recognised as a key destination for complex medical treatments and high-end care worldwide. POAstraZeneca made a major move today with its experimental COPD drug tozorakimab, reporting that the treatment significantly reduced moderate-to-severe flare-ups of chronic obstructive pulmonary disease (COPD) in two late-stage Phase III trials.This marks one of the strongest clinical results in the tough COPD drug space and pushed the company's shares higher as investors reacted to the news. Tozorakimab met its primary endpoints in the OBERON and TITANIA studies, showing statistically significant and consistent reductions in exacerbations compared with placebo across a broad group of patients.The trials enrolled thousands of adults with a history of moderate or severe flare-ups, including both current and former smokers, and the results held regardless of disease severity or blood marker levels.What makes this COPD drug result stand out is its target: tozorakimab is an IL 33 targeting monoclonal antibody, designed to block an inflammatory pathway linked to lung damage and mucus problems in COPD. This IL?33 approach is the first of its kind to show such clear success in confirmatory Phase III studies and could open the door to a new class of treatment for patients with limited options.The positive readout has already reverberated beyond clinical circles. AstraZeneca's stock climbed in markets as traders welcomed the potential long?term value from tozorakimab's development. Analysts have cited the therapy's broad applicability and the size of the COPD market as reasons for upbeat sentiment.AstraZeneca plans to share full data details at an upcoming medical conference later this year. If regulators agree that the results are compelling, tozorakimab could become a major new treatment for chronic obstructive pulmonary disease, helping patients breathe easier and reducing the risk of life threatening flare-ups. PO
< Page 8 | Page 10 >